Foghorn Therapeutics Inc.
FHTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7.9% | 27% | 108.4% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -145.3% | 88.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -183.9% | -225.4% | -371.1% | -813.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -194.4% | -237.3% | -316.4% | -682.9% |
| EPS Diluted | -0.25 | -0.28 | -0.3 | -0.31 |
| % Growth | 10.7% | 6.7% | 3.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |